Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer

Oncotarget. 2017 Apr 4;8(14):22863-22875. doi: 10.18632/oncotarget.15282.

Abstract

The identification of biomarkers of biochemical recurrence (BCR) in prostate cancer (PCa) patients undergoing radiotherapy (RT) represents an unanswered clinical issue. The primary aim of this study was the definition of new genetic prognostic biomarkers in DNA repair genes (DRGs), considering both BCR and overall survival (OS) as clinical end-points. The secondary aim was to explore the potential clinical impact of these genetic variants with the decision curve analysis (DCA) and the sensitivity analysis.We analyzed 22 germline polymorphisms in 14 DRGs on 542 Caucasian PCa patients treated with RT as primary therapy. Significant associations were further tested with a bootstrapping technique. According to our analyses, ERCC2-rs1799793 and EXO1-rs4149963 were significantly associated with BCR (p = 0.01 and p = 0.01, respectively). Moreover, MSH6-rs3136228 was associated with a worse OS (p = 0.04). Nonetheless, the DCA and the sensitivity analyses gave no ultimate response about the clinical impact of such variants.This study highlights the potential prognostic role of polymorphisms in DRGs for PCa, paving the way to the introduction of not invasive tools for the personalization of patients management. Nonetheless, other prospective studies are necessary to ultimately clarify the clinical impact of pharmacogenetics in PCa.

Keywords: DNA repair; biochemical recurrence; overall survival; polymorphisms; prostate cancer.

MeSH terms

  • Aged
  • Aged, 80 and over
  • DNA Repair*
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Neoplasm Recurrence, Local / genetics*
  • Polymorphism, Genetic
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / radiotherapy*
  • Survival Analysis